热线电话:+86 512 6799 8818

在线咨询

TOP

*姓名

*电话

邮箱

咨询内容

*验证码

联系销售


Sales Image

联系销售助理


Sales Assistant Image

联系PM


PM Image
Consult Now
How GentleGen leverages ASO to write a new chapter in precision therapy amid the oligonucleotide wave
2026-06-25
How GentleGen leverages ASO to write a new chapter in precision therapy amid the oligonucleotide wave
Against the backdrop of rapid global growth in the small nucleic acid therapeutics market, antisense oligonucleotide (ASO) technology has demonstrated core value in the field of precision medicine. The commercial landscape for small nucleic acid therapeutics experienced a significant surge in 2025–2026, highlighted by GSK's Bepirovirsen achieving milestone progress toward a "functional cure" for hepatitis B. The efficacy and safety of ASO drugs are highly dependent on sequence design and chemical modification strategies. Leveraging its intelligent design platform and flexible synthesis production lines, GentleGen empowers early‑stage R&D and process scale‑up for small nucleic acid therapeutics.
View More
From genes to antibodies with one-stop services, how does GentleGen's fully automated platform rewrite the rules of innovative drug R&D?
2026-06-25
From genes to antibodies with one-stop services, how does GentleGen's fully automated platform rewrite the rules of innovative drug R&D?
Accelerating antibody drug discovery and development remains an enduring priority in the biopharmaceutical industry. While traditional R&D workflows continue to grapple with lengthy lead times and prohibitive costs, GentleGen——a leading gene‑technology application platform——has leveraged its proprietary GentSynExp 3.0 G‑Lab fully automated platform to decisively break this deadlock.
View More
Global antibody drug industry trends: Emerging Leader in Automated Gene Services—GentleGen
2026-06-25
Global antibody drug industry trends: Emerging Leader in Automated Gene Services—GentleGen
The global antibody drug market is maintaining structural growth on a trillion‑dollar scale. In 2025, the global antibody market was valued at approximately $240 billion, and is projected to reach $460 billion by 2035, representing a compound annual growth rate (CAGR) of 6.7%. Growth drivers are rapidly shifting from traditional monoclonal antibodies to next‑generation modalities, with ADCs and bispecific antibodies emerging as the core engines. GentleGen is the first gene technology platform in China to achieve end‑to‑end automated scale‑up applications, powered by a core of "automation and intelligence," and offers one‑stop solutions covering gene synthesis, sequencing, editing, and expression.
View More
2026 Dual-Target siRNA Year Anniversary: Clinical Breakthroughs and Dual Validation of Billion-Yuan Transactions!
2026-06-25
2026 Dual-Target siRNA Year Anniversary: Clinical Breakthroughs and Dual Validation of Billion-Yuan Transactions!
Since the first siRNA drug was approved in 2018, small interfering RNA (siRNA) therapeutics have demonstrated clinical value in rare diseases, metabolic disorders, and other areas. However, in complex diseases driven by dysregulated multi‑gene networks – such as cancer and cardiovascular diseases – single‑target strategies often fall short. This has given rise to dual‑target siRNA technology, which is emerging as one of the most promising directions in RNA interference (RNAi) therapeutics. Since 2026, this field has witnessed intensive breakthroughs, transitioning from technical validation to clinical‑stage pipelines.
View More
GentleGen's G-Lab fully automated platform enables efficient delivery from gene synthesis to antibody expression within 7-10 days
2026-06-25
GentleGen's G-Lab fully automated platform enables efficient delivery from gene synthesis to antibody expression within 7-10 days
GentleGen leverages its self‑developed GentSynExp 3.0 G‑Lab, a fully automated gene and antibody platform, to build a one‑stop solution covering the entire workflow from gene design, synthesis, and validation to protein expression and antibody development. With its technological advantages in automation, high throughput, and high precision, the company provides the industry with efficient, stable, and cost‑effective R&D support.
View More
Solving the pain points of RNAi experiments: GentleGen's shRNA "Three-for-One" service, say goodbye to "mystical" knock-down methods, and obtain guaranteed shRNA!
2026-06-25
Solving the pain points of RNAi experiments: GentleGen's shRNA "Three-for-One" service, say goodbye to "mystical" knock-down methods, and obtain guaranteed shRNA!
GentleGen introduces its shRNA "Three‑for‑One" Guarantee Service, which promises that, provided the transfection efficiency meets the required threshold, at least one out of three designed shRNA constructs will achieve a minimum of 70% mRNA knockdown. Upon request, we also provide a parallel shRNA lentiviral packaging "Three‑for‑One" service, with a guaranteed titer of ≥1E+8 TU/mL and a knockdown efficiency of ≥70%. This standardized, streamlined workflow eliminates the unpredictable "black‑box" frustrations that often plague RNAi experiments.
View More
From Rare Diseases to the Era of Chronic Diseases: Breakthrough Paths and Potential Challenges in Oligonucleotide Drug R&D!
2026-06-24
From Rare Diseases to the Era of Chronic Diseases: Breakthrough Paths and Potential Challenges in Oligonucleotide Drug R&D!
Oligonucleotide drugs are at a pivotal turning point, transitioning from rare diseases to the era of chronic conditions. Key pipelines targeting weight loss, lipid-lowering, and hypertension have achieved critical breakthroughs, while the global market is experiencing accelerated growth. Notably, the total value of out-licensing deals for China-developed small nucleic acid drugs has already surpassed $15 billion.
View More
Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code
2025-04-24
Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code
On April 17, 2025, the International Institute of Molecular and Cell Biology in Warsaw, the University of Warsaw, the Medical University of Warsaw and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences jointly published in Nature, "Re-adenylation by TENT5A enh ances efficacy of SARS-CoV-2 mRNA vaccines" research has brought a new breakthrough to this problem - it is found that TENT5A polymerase can prolong the poly (A) tail of mRNA, stabilize mRNA and enhance immunity. The originality reveals the key mechanism of the efficacy of mRNA vaccine. The stability of mRNA molecules by TENT5A enzyme is a universal mechanism, so it has great potential in medicine.
View More
GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!
2024-11-04
GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!
RNAi is an intracellular post-transcriptional gene regulatory mechanism that was discovered in 1998 by Andrew Fire, Craig Mello and others in the Cryptomeria japonica nematode. It was shown that double-stranded RNA can trigger RNAi to catalyze the degradation of complementary mRNA transcripts in Cryptobacterium hidradii nematodes.Andrew Fire, Craig Mello won the Nobel Prize for this in 2006. After 20 years of technology development, the first siRNA drug was approved for marketing and clinical translation in 2018.
View More
Suzhou Junliang Biotechnology Co., Ltd. will accept samples during the Dragon Boat Festival.
2024-10-24
Suzhou Junliang Biotechnology Co., Ltd. will accept samples during the Dragon Boat Festival.
Vacation is approaching, our service program is normal to receive samples, during the vacation period, if you have special needs, please contact the local sales directly. Thank you very much for your trust and support, Junzhong Bio will be committed to oligonucleotide synthesis and modification, gene synthesis, antibody technology research and development and application!
View More
12345
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!